myTomorrows

Home
myTomorrows

myTomorrows is an international platform that links patients facing unmet medical needs to treatments in development worldwide.

We bridge the gap between patients who are searching for treatment options and the pharmaceutical companies who provide them At myTomorrows, we believe everyone should be able to access the treatment options which are open to them. We strive to make it easier for physicians and their patients with unmet medical needs to find, get information about, and access pre-approval medicines whenever possible. We believe that by making the process of accessing pre-approval medicines more transparent, we’ll be able to transform the lives of people all over the world. To contact us, please visit https://www.mytomorrows.com/en/get-in-contact.

05/02/2026

On March 10–11, the 2nd edition of the “Pre-Approval Access to Medicines in APAC conference” returns to Singapore.🌏

The conference brings together stakeholders from biopharma, patient advocacy, policy, and government to exchange practical perspectives on access to locally unauthorized medicines outside of clinical trial settings.

As APAC continues to grow in importance, discussions will focus on how pre-approval access decisions made today can shape longer-term pathways toward sustainable, responsible access across the region, while acknowledging the diversity of regulatory maturity, healthcare infrastructure, and patient needs.

This forum is a critical opportunity for stakeholders to engage in shaping the future of access in APAC, learn from regional and global peers, and contribute to the development of more sustainable models.

➡️ Check out the updated agenda and speaker lineup: https://eu1.hubs.ly/H0rwfBF0

👉 Register here: register: https://eu1.hubs.ly/H0rwftk0

This is a must-attend event for organizations actively navigating pre-approval access in the region.

05/02/2026

We are heading to Treat-NMD International Conference 2026 in Lisbon next week 🇵🇹 - sharing what 8 years of patient navigation in neuromuscular diseases has taught us about who gets into trials, and who doesn't.

At myTomorrows, we support thousands of patients every year.
🔹 Families dealing with diagnostic uncertainty.
🔹 Long drives - 6 hours or more - to reach the nearest site.
🔹 Children whose disease is progressing faster than eligibility windows allow.

These people aren't facing a "recruitment challenge." They are facing a system that wasn't designed with patients in mind.

🎤 In our session " 8 Years of Listening: What Patient Journeys in Neuromuscular Disease Teach Us About Recruitment, Expanded Access, and Equity” on February 12, at 17:10, we will share more about:

☑️ Why families say no to trials: It’s not about willingness.
☑️ How patient navigators see gaps that CROs, sponsors & other stakeholders often miss.
☑️ Where expanded access and real-world data can capture evidence from patients excluded by strict eligibility criteria.

Of course, we can revisit the need for greater awareness, discuss clinical trials, or talk about the urgency of improving enrollment metrics.

But we believe the real work is in building research pathways that truly serve the NMD community, including those who have been systematically left out.

👉 If you are there, stop by booth 12 to meet the team: Dennis Akkaya, Chief Commercial Officer, Adrianne Rivard, Senior Community Development Manager, Romina Dibra, MD, Senior EAP Site Manager, and Terri Ellsworth, Patient Liason.
🔗 You can also book a meeting with us: https://eu1.hubs.ly/H0rvLC-0

We hope to see you in Lisbon - Até já

04/02/2026

When approved treatments are exhausted, time becomes the most precious resource. ⏳

Yet for many patients, especially those living with rare diseases, access to clinical trials or when appropriate, expanded access programs, means navigating fragmented information, unclear eligibility criteria, and slow manual workflows all at times when urgency is highest.

🎙️ Our COO, Vanessa Lemarié, explores that reality in her recent conversation with Karen Jagoda on the Empowered Patient Podcast. In the episode, Vanessa discusses some of the most pressing challenges in today’s clinical trial ecosystem:

🔹Many patients are never informed about clinical trials, let alone about expanded access options when appropriate, limiting awareness for potential care opportunities.
🔹Manual trial-matching is slow and inconsistent, with increased missed eligibility for targeted and biomarker-driven studies.
🔹Lengthy recruitment timelines delay study enrollments and dosing schedules, impacting science progression and evidence generation.
🔹Geography, travel burden, and skewed site locations, disproportionately limit access to rural and underserved communities.

For rare disease patients, these challenges are even more pronounced, as trials are increasingly targeted and eligibility pathways more specific, making access harder to navigate despite growing trial activity.

That’s where technology can make a real difference.

Vanessa shares how myTomorrows AI-powered platform supports physicians pre-screen patient information to assess potential eligibility for clinical trials, and where appropriate, expanded access. This approach helps to:

☑️ Reduce trial-matching time by ~90%, improving timely visibility of relevant options.
☑️ Improve matching accuracy, reducing missed eligibility in targeted and biomarker-driven studies.
☑️ Extend reach beyond traditional trial hubs, by enabling remote pre-screening and earlier eligibility assessment at specialists and community centers.

During Rare Disease Awareness Month, this conversation is a timely reminder that innovation plays a critical role in removing barriers and improving access to clinical research, ensuring no patient is left without options.

🎧 Listen to the full conversation on the Empowered Patient Podcast: https://eu1.hubs.ly/H0rtT6r0

04/02/2026

Cancer affects millions of people worldwide. 🌍
Behind every diagnosis is a person, a family, and a unique story.

World Cancer Day is a moment to recognize those experiences, raise awareness, and mobilize action to address the global cancer epidemic. The 2025–2027 theme, “United by Unique” builds on this by calling for a more people-centered care that sees the person beyond the disease and puts individuals - not just cancer - at the heart of every decision.

People-centered care means:

🤝 Collaboration
Listening to what matters to individuals, acknowledging their concerns with empathy, and empowering them to actively participate in the decision-making process.

💬 Connection
Recognizing the importance of social ties by engaging individuals, families, and communities beyond the clinical setting.

👥 Community
Supporting informed and engaged communities to improve health literacy, self-care, and ensure healthcare systems reflect real-world needs.

At myTomorrows, our people-centered approach focuses on helping patients and caregivers learn more about clinical trial options when standard of care is no longer an option. 💚

Our Patient Navigators work closely with individuals to understand their situation, what trial options may be relevant, support informed conversations with treating physicians, and share clear, practical information to help people better understand clinical research pathways.

Because meaningful cancer care starts with understanding the person behind the diagnosis.

# Oncology

29/01/2026

Next week, our myTomorrows team, Dennis Akkaya, Danny den Hammer, Christa Reefman, Adèle Bazerque and Madeleine Pagel, will be heading to Orlando for SCOPE US 2026, and we are excited to share a session that hopefully cuts a bit through the noise.

👉 Join our Lunch Presentation “Patient and physician-driven recruitment for rare disease and targeted therapies” on Wednesday, 4 February, from 12:30-12:55 PM on the Patient Recruitment & Engagement Track.

As clinical trials become more complex, with highly specific eligibility criteria and dispersed patient populations, the way we drive enrolment must evolve.

💡In this session, we will cover how rare and targeted trials require a different recruitment approach, how platform‑enabled patient‑ and physician‑driven models deliver access and certainty, and how insights loop through Patient Navigators accelerates enrolment.

If you are working in rare or targeted populations and feeling the limits of traditional recruitment tactics, join us over lunch to explore what a different approach can unlock.

And while you are there, stop by booth #1417 for a live demo (and grab some chocolates) 💚

➡️ You can also book a meeting with us: https://eu1.hubs.ly/H0rlh1M0

See you in Orlando!

28/01/2026

Tomorrow is the day! Last chance to register for our webinar “From Ethical Guidance to Global Action: Navigating Post-Trial Access”

📅 Thursday, January 29th
🕔 4:00pm CET / 10:00am ET

💡Why this conversation matters
Post-Trial Access (PTA) continues to gain attention as clinical trials become more global and ethical guidance evolves. Many BioPharma teams are considering how PTA principles can be reflected in trial planning, coordination, and patient support across regions.

🔍 What we’ll unpack together
🔹The real-world access challenges that occur following clinical trial completion and how evolving ethical guidance for PTA impacts planning and decision making along the development path.
🔹 Core guiding principles for PTA and practical strategies for translating them into actionable plans, including selecting fit-for-purpose PTA mechanisms and exit planning.
🔹 Common challenges in PTA planning and implement solutions to ensure seamless patient access and ethical compliance.

🎤 Who you’ll hear from
🔹Olga Andreeva, Head of Expanded Access Center of Excellence, Novo Nordisk
🔹Stephanie Ferket, Director, Expanded Access Strategy & Customer Success, myTomorrows
🔹 John Massarelli, Pre-approval Access Specialist, myTomorrows (as moderator)

If you work in BioPharma across Patient Recruitment or Expanded Access (EAP), this session offers relevant perspectives grounded in real-world experience.
👉 Register now: https://eu1.hubs.ly/H0rjF0W0

22/01/2026

⏳ 1 week to go!

Our upcoming myTomorrows webinar, “From Ethical Guidance to Global Action: Navigating Post-Trial Access,” is just one week away. Have you already registered?

📅 Thursday, January 29th
🕔 4:00pm CET / 10:00am ET

Join Olga Andreeva, Head of Expanded Access Center of Excellence at Novo Nordisk, Stephanie Ferket, Director, Expanded Access Strategy & Customer Success at myTomorrows, and John Massarelli, Pre-approval Access Specialist at myTomorrows, as they discuss how evolving ethical guidance and real-world experience are shaping post-trial access approaches in today’s global clinical trials.

💡Why attend?
✔️Understand the real-world access challenges that occur following clinical trial completion and how evolving ethical guidance for PTA impacts planning and decision making along the development path.
✔️Identify core guiding principles for PTA and explore practical strategies for translating them into actionable plans, including selecting fit-for-purpose PTA mechanisms and exit planning.
✔️Recognize common challenges in PTA planning and implement solutions to ensure seamless patient access and ethical compliance.

👉 Register now to save your spot: https://eu1.hubs.ly/H0r8tn20

19/01/2026

📢 Join our growing team! Become a part of our dynamic group of Mighties with diverse backgrounds in Medical, Pharma, Tech, and Business. This is an exciting opportunity to join our ambitious company as it grows.

With benefits like flexible working, a learning and development budget, and an annual performance bonus, you’ll be based in Amsterdam with a fast-growing company of 80+ people, with 30 nationalities, helping patients to know all their treatment options. 💚

✔️Event Marketer: https://eu1.hubs.ly/H0r1w6N0
✔️Program Manager, Clinical Trial Operations: https://eu1.hubs.ly/H0r1xlZ0
✔️Director of Operational Excellence: https://eu1.hubs.ly/H0r1wkN0

👉 Our full list: https://eu1.hubs.ly/H0r1wmM0

14/01/2026

🧠 How can physical therapy support people affected by ALS?

Living with Amyotrophic lateral sclerosis (ALS) brings gradual physical changes that can affect movement, balance, and breathing over time. While there is currently no cure, supportive care plays an important role in helping people maintain comfort, mobility, and quality of life.

Physical therapy is one key part of this supportive approach. It can help people stay active for as long as possible, reduce stiffness and discomfort, support breathing, and improve overall well-being.

💡 In our latest blog, we take a closer look at how physical therapy fits into ALS care, with a focus on practical strategies that may help people adapt as needs change.

📖 We explore:
✔️What is ALS and how symptoms can progress over time
✔️The role of physical therapy in maintaining mobility and flexibility
✔️Mobility exercises for ALS, including stretching, range-of-motion, balance, and low-impact aerobic activity
✔️Breathing techniques and supportive respiratory strategies
✔️Assistive devices and home modifications that can improve safety and independence

🔗 Read the full blog here: https://eu1.hubs.ly/H0qYQdh0

Whether you are living with ALS, caring for someone who is, or simply looking for clear and easy-to-understand information, this blog aims to offer an accessible overview of how physical therapy may support daily life with ALS.

💚 This article is part of our broader effort to provide reliable, patient-focused resources on neurodegenerative conditions. For more topics, visit our Neurodegenerative Patient Resource Page, where we’ve gathered insights on conditions like MSA, Parkinson’s, ALS and more.

👉 https://eu1.hubs.ly/H0qYQvS0

08/01/2026

📢 Post-Trial Access: A Growing Priority for BioPharma in Global Clinical Development

As clinical trials expand across borders, Post-Trial Access (PTA) is becoming a critical focus for BioPharma organizations. With evolving ethical guidance and increasing expectations around patient continuity of care, companies are adapting their strategies to deliver effective, compliant, and patient-centered PTA solutions.

In our upcoming webinar, “From Ethical Guidance to Global Action: Navigating Post-Trial Access”, we’ll explore how recent updates to ethical frameworks, including CIOMS and the Declaration of Helsinki, are influencing PTA planning and decision-making across global programs.

📅 Thursday, January 29th
🕔 4:00pm CET / 10:00am ET

Our panel of experts will share practical insights into guiding principles, strategic considerations, and common challenges, highlighting approaches to translate ethical commitments into actionable, real-world PTA solutions worldwide.

🎙 Speakers:
• Olga Andreeva, Head of Expanded Access Center of Excellence, Novo Nordisk
• Stephanie Ferket, Director, Expanded Access Strategy & Customer Success, myTomorrows

🎤 Moderator: John Massarelli, Pre-approval Access Specialist, myTomorrows

👉 Register here: https://eu1.hubs.ly/H0qNJG60

05/01/2026

BIO Partnering Week 2026 is just around the corner, and our team is looking forward to connecting with industry leaders, innovators, and investors from across the life sciences sector during this key healthcare investment event.

📅 January 12–15, 2026
📍 San Francisco, US

As the world's largest healthcare investment symposium, BIO Partnering Week brings together a broad range of stakeholders, including professionals from biotechnology and pharmaceutical research and development, investment sectors, digital therapeutics, government agencies, and patient advocacy organizations.

Our very own Dennis Akkaya, Chief Commercial Officer, and Stephanie Ferket, Director, Expanded Access Strategy & Customer Success at myTomorrows, will be attending to listen, learn, and engage in conversations around the latest developments across biotech and biopharma - from innovation and investment dynamics to evolving approaches in clinical development and patient access

💬 Interested in meeting Dennis and Stephanie during JPM Week?
👉 Book a meeting with them for thoughtful, industry-focused discussions: https://eu1.hubs.ly/H0qJ08n0

31/12/2025

Happy 2026 from myTomorrows! Here’s to a new year filled with health, progress, and meaningful moments. 🎉

💚 As we look back on the past year, we’re reminded that everything we do begins and ends with patient care. Whether that’s a patient reaching out for support in a time of need, exploring potential next steps, or trying to navigate a complex and unfamiliar treatment landscape. Our goal is to bring clarity and certainty to these moments through personalized support.

In 2025, we had the privilege of working alongside thousands of patients, families, physicians, and partners across the world. Together, we worked to reduce access barriers and bring greater transparency to the complex pre-approval landscape. ☀️

As we step into the new year, our focus remains clear: to continue to build innovative solutions that make the discovery and access to emerging therapies easier and more transparent. We believe that every patient deserves to know their options, and we are dedicated to making that a reality. 💪

Warm wishes from all our Mighties.

Address

Website

https://myTomorrows.com/

Alerts

Be the first to know and let us send you an email when myTomorrows posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to myTomorrows:

Shortcuts

Want your practice to be the top-listed Clinic?

Country:

City:

05/02/2026

05/02/2026

04/02/2026

04/02/2026

29/01/2026

28/01/2026

22/01/2026

19/01/2026

14/01/2026

08/01/2026

05/01/2026

31/12/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share